Durham, NC-based Aldagen has added $9 million in new money for its third round, bringing total investment in the Series C to $23 million. That money will be put to use developing new stem cell therapies. Aldagen was founded in 2000 and is developing programs with technology initiated at Duke University. Researchers at the company have been developing adult stem cell therapies for leukemia, damaged heart muscles and more. Its third round is expected to be enough to fund the company until mid-2009. CNF Investments and Tullis-Dickerson are now betting on the company's success.
Aldagen gains $17.3M in financing. Report